Abstract | BACKGROUND: OBJECTIVE: METHODS: This study is based on data from the Swiss association for joint tasks of health insurers. Time to relapse and 12-month confirmed disability progression were compared between treatment groups using multivariable Cox regression analysis with confounder adjustment. Inverse-probability weighting was applied to correct for the bias that patients on fingolimod have a higher chance to remain relapse-free than patients on IFN/GA. RESULTS: We included 1640 patients (64% IFN/GA, 36% fingolimod, median total follow-up time = 4-5 years). Disease-modifying treatment (DMT) groups were well balanced with regard to potential confounders. Disability progression was observed in 155 patients (8.8%) on IFN/GA and 51 (7.6%) on fingolimod, of which 44 and 23 were relapse-free during the initial DMT, respectively. Adjusted standard regression analysis on all patients indicated that those on fingolimod experience less frequently disability progression compared with IFN/GA (hazard ratio = 0.53 (95% confidence interval = 0.37-0.76)). After bias correction, this was also true for patients without relapses (hazard ratio=0.56 (95% confidence interval = 0.32-0.98). CONCLUSION: Our analysis indicates that fingolimod is superior to IFN/GA in preventing disability progression in both relapsing and relapse-free, young, newly diagnosed RRMS patients.
|
Authors | Viktor von Wyl, Pascal Benkert, André Moser, Johannes Lorscheider, Bernhard Décard, Peter Hänni, Carmen Lienert, Jens Kuhle, Tobias Derfuss, Ludwig Kappos, Özgür Yaldizli |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 27
Issue 3
Pg. 439-448
(03 2021)
ISSN: 1477-0970 [Electronic] England |
PMID | 32463336
(Publication Type: Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Glatiramer Acetate
- Interferon-beta
- Fingolimod Hydrochloride
|
Topics |
- Fingolimod Hydrochloride
(therapeutic use)
- Glatiramer Acetate
(therapeutic use)
- Humans
- Immunosuppressive Agents
- Interferon-beta
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy)
- Recurrence
|